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ABSTRACT
Objective In this pilot study, the effect of sildenaﬁ  l on 
digital ulcer (DU) healing and related clinical symptoms 
was analysed.
Methods A total of 19 patients with systemic sclerosis 
(SSc) were treated with maximally tolerated sildenaﬁ  l 
doses up to 6 months. Primary outcome was the healing 
of DUs. Changes in other clinical symptoms were also 
evaluated.
Results In all, 49 DUs were present at baseline; this 
decreased to 17 ulcers (p<0.001) at the end of sildenaﬁ  l 
treatment. Furthermore, the visual analogue scale 
(VAS) score for Raynaud’s phenomenon (RP), pain and 
activity improved (p=0.003, p=0.002 and p=0.05, 
respectively). A total of 9 patients developed 12 new DUs 
during sildenaﬁ  l treatment.
Conclusions This study indicates an effect of sildenaﬁ  l 
on DU healing in patients with SSc and an improvement 
of RP and associated symptoms that should be validated 
in controlled studies.
INTRODUCTION
Systemic sclerosis (SSc) is a devastating disease 
with a high impact on quality of life and prog-
nosis. Vasculopathy is an early and prominent 
feature and is reﬂ   ected by Raynaud’s phenom-
enon (RP), the presence of digital ulcers (DUs) 
and pulmonary arterial hypertension (PAH1). 
Recent therapeutic advances suggest common 
pathogenic mechanisms and a role for endothelin 
receptor activation in SSc-associated vasculopa-
thy.2 However, endothelin receptor blockers such 
as the dual endothelin receptor type A/B blocker 
bosentan are effective in the prevention of DUs, 
but are not able to heal DUs, indicating different 
mechanisms for prevention and ulcer healing.3 
Intravenous iloprost is often used for the treat-
ment of DUs, but its effect on the prevention of 
DUs has not been studied to date. There is also 
a subgroup of patients that do not respond to ilo-
prost treatment.4
Reduced levels of nitric oxide have also been 
proposed to play a role in the pathogenesis of 
vascular disease in systemic sclerosis.5 Therefore, 
sildenaﬁ  l as a selective inhibitor of cyclic guanos-
ine monophosphate (cGMP)-speciﬁ  c  phosphodi-
esterase type 5 and potent agent to increase the 
endogenous NO levels is an attractive candidate 
for the treatment of SSc-associated vasculopathy. 
Indeed, sildenaﬁ  l is approved by the US Food and 
Drug Administration and the European Medicines 
Agency for the treatment of PAH. The highest 
dose of sildenaﬁ  l recommended for the treatment 
of PAH is 60 mg daily; however, several studies 
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suggest a higher effect by increasing the dose.6 
7 In a placebo-controlled crossover study, 50 mg 
sildenaﬁ  l twice daily for 4 weeks was shown to 
be effective for the treatment of RP.8 Furthermore, 
some case reports have suggested an effect on 
DU healing in SSc.9 10 Therefore, we conducted 
a pilot study analysing the effect of sildenaﬁ  l on 
healing of SSc-associated DUs refractory to other 
treatments.
PATIENTS AND METHODS
A total of 19 patients with SSc (mean age 51 years) 
fulﬁ  lling the American College of Rheumatology 
(ACR) criteria for systemic sclerosis, assessed 
according to the European League Against 
Rheumatism (EULAR) Scleroderma Trials And 
Research (EUSTAR) criteria,11 and experiencing 
severe rhagades (n=1) or digital ulcers (n=18) refrac-
tory to treatment were treated with the maximally 
tolerated sildenaﬁ  l doses (up to 150 mg) for a maxi-
mum of 6 months. Inclusion criteria were stable 
treatment with vasoactive and immunosuppres-
sive drugs for 3 months. Current smokers, patients 
with gangrene, a history of gastric ulcers during 
the last 3 months, cardiac ejection fraction below 
25%, patients with severe organ involvement or 
other uncontrolled diseases were excluded. DUs 
were deﬁ  ned as a loss of epidermis and dermis. The 
demographic data are shown in table 1.
The study was conducted between 2004 and 
2007. Two patients were treated outside of the 
study with the intention to heal digital ulcers 
refractory to other treatments. The other 17 
patients were treated as part of a prospective, 
open, single-centre study. Here, the primary out-
come parameter was DU healing. Secondary end 
points were effects on Raynaud’s phenomenon by 
using a visual analogue scale (VAS), the preven-
tion of new ulcers, changes in VAS scores for pain, 
activity and experiencing ulcers, the improvement 
of rhagades, Scleroderma Health Assessment 
Questionnaire (SHAQ) indices and the occur-
rence of sildenaﬁ   l-related adverse effects. Drop 
out criteria/ﬁ  nal end points were any changes in 
the immunosuppressive treatments, no response 
on ulcer healing within 1 month, or escalation of 
medication with vascular effects. Relevant macro-
vasculopathy responsible for DUs was excluded 
by angiography or duplex sonography.12 Nine 
patients treated for 6 months by sildenaﬁ  l received 
a second angiography.
The study was approved by the local ethical 
committee (SDN-D-002G) and published as a clini-
cal trial (NCT00624273). Patients signed an indi-
vidual informed consent.
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Statistics
A paired Wilcoxon test was used to identify the effect of sildena-
ﬁ  l on digital ulcers and VAS for clinical symptoms. Graph Pad 
Prism V.3.02 (Graph Pad Software, San Diego, California, USA) 
for Microsoft Windows was used.
RESULTS
Three patients did not receive sildenaﬁ  l for more than 1 month 
due to myositis requiring immunosuppression (n=1), the reoc-
currence of atrial ﬁ  brillation (n=1) and infection of an ulcer with 
a multiresistant staphylococcus (n=1), and were excluded from 
further analyses. In the remaining 16 patients, the mean sildena-
ﬁ  l dose was 114 mg/day, and the mean duration of treatment 
was 5.2 months. At baseline, 49 ulcers were present (mean 3.1/
patient). Most patients showed a rapid response reaching a 
minimum of DUs within 3 months without differences in SSc 
subtype (ﬁ  gure 1A,B; ﬁ  gure 2). The minimal number of DUs was 
achieved in each patient at different time points; minimally nine 
DUs were present (mean 0.6 ulcers/patients, p<0.001 compared 
to initial numbers, table 1). At the end of sildenaﬁ  l treatment, 17 
digital ulcers were detectable (mean 1.1/patient), which was dif-
ferent from the number of ulcers at baseline (p<0.001, table 1).
During sildenaﬁ  l treatment, 9 patients developed 12 new DUs 
resulting in treatment being stopped in 3 patients. In one of 
these patients a diagnosis of calcinosis was made. A total of 12 
patients were treated for 6 months. VAS scores for RP, pain and 
activity signiﬁ  cantly improved (p=0.003, p=0.002 and p=0.05, 
respectively) with sildenaﬁ   l treatment (ﬁ   gure 1C–F). There 
was also a tendency for changes in the disability score due to 
the DUs (p=0.08). SHAQ Disability Index (SHAQ-DI) scores 
available from 11 patients improved from a mean of 0.6 (SD 
0.52) to 0.42 (SD 0.32) but failed to reach statistical signiﬁ  cance 
(p=0.14). In the nine patients that received angiography before 
and after treatment, one responder showed an improvement of 
vascular pathology (not shown). Severe rhagades disappeared 
by   sildenaﬁ  l in the one affected patient. Of the 14 patients with 
Table 1  Patient characteristics and effects of treatments including previous and concomitant treatments
Treatment Number of ulcers during treatment
Side 
effects Patient no.
Activity 
score
Systemic 
sclerosis 
(SSc) type DD (years)
Age 
(years)
Previous and 
concomitant Start
Duration 
(months)
Dosage 
(mean,
 mg/day) Start Min End
Compl 
heal New
  1 4.5 Diff 2 69 CCB, PC (4), PX January 2§   50 1 0 0 1 0 No
  2 2.0 Lim 41 51 SL, CCB, PC 
(2), ASA
October 1‡ 150 1 1 1 0 0 No
 3 3 Lim 0.5 40 PC  (3.5), 
CCB, SL, P (7.5)
September 3§ 150 3 1 2 2 1 No
  4 3.0 Diff 25 54 ACE, CCB, ASS, 
P (2.5)
February 6  50 1 0 0 1 0 No
 5 2.5 Lim 11 59 PX, PC (3), CCB, 
HQ, P (4),
February 6 150 1 0 0 1 0 E, Fl, Pa, 
Dizz, Rx
  6* 0.5 Diff 5 55 PC (1.5), SG, CCB, 
AB, ACE
April 2.5†   75 2 0 0 2 0 Dys, E, WI
 7 1.0 Lim 0.5 39 PC (5), CCB, ATB, 
P (7)
January 6 100 3 0 0 4 1 Fl, Pa, RRR, 
Rx
 8 5.0 Diff 5 58 AA, CCB, ACE, 
PC (4)
October 6 150 2 0 1 2 1 Fl
  9 1.0 Lim 3 29 CCB, PX, ASA, January 6 150 2 1 1 1 0 E
10* 1.0 Lim 6 70 PC (4), SG, 
CCB, ACE AZA, 
P (5), PX
August <1†  50 5 5 5 0 0 AF,  Dizz
11 1.0 Lim 6 48 PP, PC (2), PX, 
CCB, AC
May <1‡  75 2 2 2 0 0 No
12 2.5 Diff 2 54 CCB, ACE, PC (2.5), 
AB, ATB
May 6 125 5 0 2 5 2 RRR
13 2.0 Diff 11 43 PC (6), CCB, PX, 
P (5)
August 6   50 2 0 3 2 3 E, Fl, Pa, 
MP
14 1.0 Diff 7 43 PC (3), CCB, ASA, 
P (5)
April 6  75 4 1 2 3 1 WI,  Pa, 
RRR
15 2.0 Lim 9 60 SG, PC (3), CCB, 
ACE
January 6 150 6 2 2 5 1 No
16 2.5 Diff 22 51 SG, PC (3), PX, 
ASA
February 4§ 150 4 2 2 3 1 No
17 3.0 Diff 17 65 PC (2), PX, CCB, 
CYC, P (10)
May 6 100 6 2 2 5 1 No
18 1.5 Lim 14 38 SG, PC (5), CCB, 
PX, PP, P (7.5)
March 6 150 5 0 0 5 0 No
19 2.0 Lim 1 42 CYC, CCB, PC (2), 
AC
June 6 150 2 0 0 2 0 No
SSc type: lim, limited; diff, diffuse.
*Indicates male patients.
†Indicates cessation of treatment due to side effects.
‡Indicates cessation of treatment due to other events with possible impact on the effect of treatment (ulcer infection, cyclophosphamide use).
§Indicates patients with development of new digital ulcer or calcinosis and no signiﬁ  cant improvement by treatment.
AA, autoamputation; AB, α blocker; AC, anticoagulation; ACE, angiotensin converting enzyme inhibitor; AF, atrial ﬁ  brillation; ASA, acetyl salicylic acid; ATB, angiotensin receptor 
blocker; AZA, azathioprine; BWI, body weight increase; CCB, calcium channel blockers; compl heal, number of ulcers completely healed; CYC, cyclophosphamide; DD, disease duration; 
Dizz, dizziness; Dys, dyspnoea; E, Oedema; Fl, ﬂ  ush; HQ, hydroxycloroquine; MP, muscle pain; P, prednisone (mg/day); Pa, palpitations; PC, intravenous prostacyclin (weeks with 
maximally tolerated dose for 6 h/day); PP, plasmaphereses; PX, pentoxyphylline; RRR, reduction of RR (arterial hypertension) medication; Rx, reﬂ  ux; SG, surgery; SL, sympathicolysis.
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follow-up data available, 7 patients developed 15 DUs within 3 
months, and 3 patients took sildenaﬁ  l outside of the study.
Mild side effects were common and were present in 9 out of 
19 patients, but resulted in a discontinuation of the treatment 
only in the 2 male patients (table 1). In three patients with arte-
rial hypertension, the antihypertensive treatment was reduced 
during sildenaﬁ  l treatment.
DISCUSSION
In a previous single-centre placebo-controlled crossover study, 
sildenaﬁ  l was shown to improve the capillary blood ﬂ  ow and 
RP. As suggested by a few patients with DUs, sildenaﬁ  l could 
provide a useful therapeutic approach for DU healing. In this 
prospective, open pilot study, maximally tolerated sildena-
ﬁ  l doses seem to be effective in DU healing. The effect was 
rapid, and maximum beneﬁ   t was reached in the ﬁ  rst  few 
months. Furthermore, the study conﬁ  rmed the beneﬁ  cial effect 
of sildenaﬁ   l on RP and microvasculopathy. DUs are a very 
severe complication with a high impact on the quality of life 
in patients with SSc. At present, there is no approved treat-
ment for the healing of DUs. The dual endothelin-1 receptor 
antagonist has failed to be effective in ulcer healing.3 However, 
different studies have shown the effect of bosentan in pre-
venting the development of new DUs.3 13 In the present study, 
sildenaﬁ  l shows beneﬁ  t in DU healing, conﬁ  rming case reports 
and initial observations in which sildenaﬁ  l was given only for 
a few weeks.8 In our study, patients were treated for up to 6 
months. Within this period, a signiﬁ  cant proportion of patients 
developed new DUs, suggesting a failure of sildenaﬁ  l to prevent 
new structural defects. Furthermore, only one patient had mild 
improvement by angiography. As already suggested by others, 
different pathogenetic mechanisms could be responsible for 
prevention or DU healing.2 14 Therefore, as also discussed for 
the treatment of PAH, combination treatments targeting differ-
ent pathogenic mechanisms could provide a more valuable and 
effective tool for further treatments.
A major limitation of this study is the lack of a placebo group. 
When compared to the placebo group of the ‘Rheumatoid 
Arthritis PreventIon of structural Damage 1’ (RAPID 1) study in 
which about 10% of ulcers healed per month,3 the number of 
ulcers healed was higher in our sildenaﬁ  l group. However, direct 
comparison with other trial data provide only limited informa-
tion due to differing study designs. Furthermore, most of the 
patients treated here had been refractory to previous treatments. 
Figure 1  Effect of sildenaﬁ  l treatment on the number of digital ulcers (DU) in patients with (A) diffuse and (B) limited systemic sclerosis (SSc) during 
6 months of treatment, on (C) Raynaud’s phenomenon (RP), (D) burden of pain, (E) daily activity and (F) on disease burden due to ulcers measured by 
visual analogue scale (VAS). A paired Wilcoxon test was used to calculate statistical signiﬁ  cance; the median is illustrated as a horizontal line.
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In conclusion, this pilot study indicates beneﬁ  cial and rapid 
effects in the treatment of DUs. Moreover, sildenaﬁ  l decreases 
the burden of RP and associated symptoms. The data encour-
ages controlled studies, and combining a preventive as well as a 
curative treatment would be a valuable approach to treat DUs 
in patients with SSc.
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Therefore, our study population could represent a subgroup of 
patients with SSc truly responding to sildenaﬁ  l treatment.
For treatment of PAH or erectile dysfunction, lower doses of 
sildenaﬁ  l are usually used. In our study, maximally tolerated 
doses were given for the treatment of DUs. Treatment was well 
tolerated and side effects were not dose related. The two male 
patients who discontinued the drug due to side effects received 
low sildenaﬁ  l doses (2×25 mg/day), suggesting a higher sensi-
tivity to the drug other than the use of unconventionally high 
doses. The incidence of peripheral oedema, the presence of dys-
pnoea and reoccurrence of atrial ﬁ  brillation suggest increased 
blood ﬂ  ow and ﬂ  uid overload in few patients. This remains to 
be further evaluated since phosphodiesterase-5 inhibitors were 
also successfully used to treat pulmonary oedema.15
Figure 2  Digital ulcer healing by sildenaﬁ  l treatment as shown for 
three different patients. Digital ulcers before treatment are shown in 
(A), (C) and (D); (B), (D) and (F) show the effects of sildenaﬁ  l treatment; 
(E) and (F) come from a patient refractory to continuous intravenous 
iloprost treatment over 2 weeks requiring amputation and showing 
insufﬁ  cient wound healing. Within a few days, the patient remarked at 
ﬁ  nger rewarming and subsequently progressive wound healing.
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